YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its ...

Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...

CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and ...

A Greer couple is hosting a fundraiser to support a costly gene editing procedure for their two children, who suffer from a ...

A new CRISPR-based gene-editing therapy shows promise for treating severe high cholesterol by disabling the ANGPTL3 gene.

Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol ...